Application of Quantitative Pharmacology in Drug-Drug Interaction Risk Assessment & Management

This is Part 3 of a 3-part webinar series. Attendees that complete all three components will be awarded a certificate of completion highlighting the skills you have obtained.

In addition to the one hour lecture, there will be a 30 minute Faculty on Focus event where Faculty Speakers will be available for Q&A from Attendees! This is a rare opportunity to get direct access to the Faculty Speakers to get in-depth answers and clarification on the topics discussed during the webinar. The Fundamentals Tutorials - Clinical Applications Webinar Series provides a clinical pharmacology focused program which is relevant at every stage of your career! 

Target Audience: Professionals in academic, pharmaceutical/private sector and regulatory settings involved in drug disposition, clinical pharmacology and pharmacometrics. In addition, Students of graduate and professional doctorate programs.

Session Description: Drug-drug interactions (DDIs) may cause the drug to be more or less effective or cause untoward effects on the body. CYP-mediated or transporter-mediated small molecular DDIs have been long recognized and well characterized, and some could be clinically relevant, and few may even be fatal. The introduction of new molecular modalities (e.g., therapeutic proteins) in the pharmacotherapy in the recent decades has added further complexity to the DDI risk assessment and management. This session will provide an introduction of the major types of DDIs involving small molecules and therapeutic proteins and their mechanisms. Moreover, the utility of quantitative pharmacology in DDI propensity projection and mitigation will be illustrated using some DDI case examples and its potential impact on the current DDI assessment strategies will also be discussed.

Learning Objectives:  At the conclusion of this webinar, learners will be able to:

• Learn about the major types of DDIs and their potential impact on clinical responses;
• Understand the mechanisms of major DDIs for small molecule drugs and therapeutic proteins;
• Learn how the quantitative pharmacology approach could impact the current DDI assessment and risk management strategies.

Faculty Speaker:

• Honghui Zhou, PhD, US Head of Pharmacometrics, Clinical Pharmacology & Pharmacometrics, Janssen Research & Development LLC, Johnson & Johnson 

CE will not be offered for this webinar.